Figure 2.

Circulating miR-208b is a promising biomarker for predicting chemosensitivity of FOLFOX in CRC

(A) The level of serum miR-208b was significantly decreased in response patients compared with non-response patients (69 chemosensitivity versus 47 chemo-insensitivity). (B) Receiver operating characteristic (ROC) curve of the miRNA-208b and CEA levels. The area under the curve (AUC) for miRNA-208b was 0.771 (95% CI, 0.688–0.855), and the AUC for CEA was 0.493 (95% CI, 0.385, 0.601). (C) qRT-PCR analysis of the level of serum miR-208b. For response patients, it was significantly decreased after chemotherapy compared with before chemotherapy (n = 12). Additionally, the post-chemotherapy level of serum miR-208b was significantly increased in non-response patients compared with pre-chemotherapy (n = 12). (D) Kaplan-Meier analysis of progression-free survival (PFS) rate for response and non-response patients (p < 0.0001), and PFS with low and high serum miR-208b levels. ∗∗p < 0.01, ∗∗∗p < 0.001.